Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orexin's Role in The Neurobiology of Substance Use Disorder
NCT05630781Recruiting
- Sponsor
- National Institute on Drug Abuse
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial of suvorexant in nicotine dependence (2 arms), sponsored by National Institute on Drug Abuse. Primary endpoints: Functional Magnetic Resonance Imaging - Cue Reactivity, Cue reactivity and suvorexant effectiveness and 2 more. Started Feb 2023; status: recruiting.
02
Drugs
suvorexant
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT05630781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05630781.